CA2540501A1 - Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci - Google Patents

Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci Download PDF

Info

Publication number
CA2540501A1
CA2540501A1 CA002540501A CA2540501A CA2540501A1 CA 2540501 A1 CA2540501 A1 CA 2540501A1 CA 002540501 A CA002540501 A CA 002540501A CA 2540501 A CA2540501 A CA 2540501A CA 2540501 A1 CA2540501 A1 CA 2540501A1
Authority
CA
Canada
Prior art keywords
group
alkyl
ylcarbonyl
substituted
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002540501A
Other languages
English (en)
Other versions
CA2540501C (fr
Inventor
Frank Himmelsbach
Birgit Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International Gmbh
Frank Himmelsbach
Birgit Jung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Frank Himmelsbach, Birgit Jung filed Critical Boehringer Ingelheim International Gmbh
Publication of CA2540501A1 publication Critical patent/CA2540501A1/fr
Application granted granted Critical
Publication of CA2540501C publication Critical patent/CA2540501C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2540501A 2003-09-30 2004-09-24 Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci Expired - Fee Related CA2540501C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEDE10345875.1 2003-09-30
DE10345875A DE10345875A1 (de) 2003-09-30 2003-09-30 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
PCT/EP2004/010723 WO2005033096A1 (fr) 2003-09-30 2004-09-24 Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci

Publications (2)

Publication Number Publication Date
CA2540501A1 true CA2540501A1 (fr) 2005-04-14
CA2540501C CA2540501C (fr) 2012-05-22

Family

ID=34353273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2540501A Expired - Fee Related CA2540501C (fr) 2003-09-30 2004-09-24 Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci

Country Status (5)

Country Link
EP (1) EP1670781A1 (fr)
JP (1) JP2007507445A (fr)
CA (1) CA2540501C (fr)
DE (1) DE10345875A1 (fr)
WO (1) WO2005033096A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100709909B1 (ko) 1999-06-21 2007-04-24 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 비사이클릭 헤테로사이클, 이를 함유하는 의약 조성물 및 이의 제조방법
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
CA2833852C (fr) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
CA2665804A1 (fr) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Compose d'uree ou sel dudit compose
KR20090074202A (ko) 2006-09-18 2009-07-06 베링거 인겔하임 인터내셔날 게엠베하 Ｅｇｆｒ 돌연변이를 갖는 암을 치료하는 방법
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295468B6 (cs) * 1996-04-12 2005-08-17 Warner-Lambert Company Polycyklické sloučeniny
CA2361174C (fr) * 1999-02-27 2009-10-27 Boehringer Ingelheim Pharma Kg 4-aminoquinazoline et derives de quinazoline ayant un effet inhibiteur sur la transduction du signal assiste par les tyrosine-kinases
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
KR100709909B1 (ko) * 1999-06-21 2007-04-24 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 비사이클릭 헤테로사이클, 이를 함유하는 의약 조성물 및 이의 제조방법
ATE413394T1 (de) * 2000-06-24 2008-11-15 Astrazeneca Ab Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2002044166A1 (fr) * 2000-11-02 2002-06-06 Astrazeneca Ab Quinolines substituees comme agents antitumoraux
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы

Also Published As

Publication number Publication date
CA2540501C (fr) 2012-05-22
JP2007507445A (ja) 2007-03-29
WO2005033096A1 (fr) 2005-04-14
DE10345875A1 (de) 2005-04-21
EP1670781A1 (fr) 2006-06-21

Similar Documents

Publication Publication Date Title
CA2476008A1 (fr) Composes heterocyclique bicyclique, compositions pharmaceutiques contenat ces composes, leur utilisation et procede de preparation
TW200302221A (en) Quinazoline derivatives
CN108697714A (zh) 新型稠合嘧啶化合物或其盐
US20090036474A1 (en) Quinazoline derivatives for use against cancer
NZ554017A (en) [(Quinazolin-4-yloxy)phenyl]acetamide derivatives
JP2005529090A5 (fr)
AU2010217929A1 (en) JAK kinase modulating quinazoline derivatives and methods of use thereof
CN101415688A (zh) 具有b-raf抑制活性的喹唑啉酮衍生物
AU2013210438A1 (en) Pyrazine carboxamide compound
KR20100089090A (ko) 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
AU2004282179A1 (en) Protein kinase inhibitors
TW200301702A (en) Quinazoline derivatives
CN101415689A (zh) 具有抗癌活性的经取代的喹唑啉
AU2012308681A1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
CA2693880A1 (fr) Derives pyrimindines 934
JP2009528335A (ja) キナゾリン誘導体
AU2011296024A1 (en) Quinazoline compounds and methods of use thereof
CN104447765A (zh) 三环化合物及其药物组合物和应用
US20090036485A1 (en) Quinoline derivatives
CA2540501A1 (fr) Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci
ZA200406070B (en) 4-(N-Phenylamino)-Quinazolines/Quinolines as tyrosine kinase inhibitors
WO2017090719A1 (fr) Composé pyrimidine condensé ou sel de celui-ci
WO2003053960A2 (fr) Composes chimiques
CN114105887A (zh) 一种氨基嘧啶衍生物及其制备方法和用途
JP2007507445A5 (fr)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130924